Taladegib (ENV-101)
Taladegib: A Hedgehog Pathway Inhibitor Designed for Fibrotic Diseases
Endeavor’s lead therapeutic candidate, taladegib (ENV-101), is a Hedgehog (Hh) signaling pathway inhibitor in clinical development. The Hh pathway facilitates key biological mechanisms that drive fibrosis. Clinical proof of concept in idiopathic pulmonary fibrosis (IPF) has validated the therapeutic potential of Hedgehog pathway inhibition.
A Pathway-Based Approach to Fibrosis
Taladegib was developed from Endeavor’s research into the biological mechanisms that drive fibrosis and disease progression. Through this work, Endeavor identified the Hedgehog signaling pathway as a causative mediator of fibrosis across many organs and tissues in the human body.
Taladegib is intended to address multiple mechanisms involved in disease progression through a single therapeutic approach.
Designed to Address the Underlying Biology of Disease
Hedgehog signaling influences both mechanical signals associated with extracellular matrix stiffness and biochemical signals associated with inflammatory activity, two key drivers of myofibroblast activation and persistence. Because the pathway sits upstream of these interconnected processes, targeting Hedgehog signaling may offer a more complete approach to addressing the underlying drivers of fibrotic diseases.
Endeavor believes this approach has the potential to do more than simply slow disease progression.
Validating a New Approach to Fibrosis
Clinical proof of concept established in IPF has provided important support for the therapeutic potential of Hedgehog pathway inhibition and reinforced Endeavor’s understanding of fibrosis biology. These findings continue to inform the development of taladegib and support Endeavor’s efforts to unlock the therapeutic potential of Hedgehog signaling across a range of fibrotic diseases.
As Endeavor advances taladegib through clinical development, the program remains the foundation of the company’s fibrosis-focused strategy and commitment to developing innovative therapies for patients with high unmet need.